Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal

PHASE3CompletedINTERVENTIONAL
Enrollment

1,761

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

SIIL Live Attenuated Influenza Vaccine

Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010

BIOLOGICAL

Matched placebo

Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.

Trial Locations (1)

Unknown

Institut de Recherche pour le Développement (IRD), Niakhar station, Niakhar

All Listed Sponsors
collaborator

Institut de Recherche pour le Developpement

OTHER_GOV

collaborator

Institut Pasteur de Dakar

OTHER

collaborator

Centers for Disease Control and Prevention

FED

lead

PATH

OTHER

NCT01854632 - Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal | Biotech Hunter | Biotech Hunter